Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 4
Submit an article Journal homepage
377
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States

Xiaomeng Yuea The James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USACorrespondence[email protected]
,
Ana L. Hincapiea The James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA
,
Yuxiang Lib College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA
&
Jeff J. Guoa The James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA
Pages 946-954 | Received 08 Jun 2021, Accepted 26 Oct 2021, Published online: 15 Nov 2021

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.